Assessment of Biopharmaceutical Immunogenicity: A Review

Anurag Rathore^*
*Correspondence: Anurag Rathore, Department of Chemical Engineering, Indian Institute of Technology Delhi, New Delhi, India, Email:

Keywords

Biopharmaceutical • Immunogenicity • Drug disposition

Introduction

Discussion is held about the current effects of the Biopharmaceutics Drug Disposition Classification System (BDDCS) and Biopharmaceutics Classification System (BCS) on relevant scientific developments. One of the significant BCS achievements is the extensive research done on the dissolution of poorly absorbed BCS class II medications in nutritious liquids (such milk and peanut oil) and biorelevant media for the exact prediction of the rate and degree of oral absorption. Furthermore, the use of physiologically based pharmacokinetic (PBPK) modelling as a tool for predicting bioavailability is highlighted. In regard to the biopharmaceutical categorization of medications, the ignored reaction-limited dissolution models are explored [1,2]. This is due to recent dissolution investigations showing simultaneous operation of the two processes, diffusion-limited dissolution and reaction-limited dissolution.

Discussion

Applications of the BDDCS to the understanding of dispositional phenomena are addressed, along with formulation techniques that improve solvability and dissolution based on the supersaturation principle. The most recent categorization schemes that are pertinent to either the BCS or the BDDCS are shown at the end. Here are a few: the "system," which is a continuous version of the BCS; the "ECCS," which is a model-independent method based on % metabolism and whether or not the present regulatory dissolution conditions are satisfied. By skipping the metric of solubility, ECCS differs from BDDCS (based on the assumption that since it interrelates with lipophilicity, it is not directly relevant to clearance mechanisms or elimination). Physicochemical characteristics and membrane permeability are used by ECCS to categorise substances.

Another problem is the biopharmaceutical drug formulation's high and fluctuating viscosity. In clinical contexts, the usage of monoclonal antibodies is growing. However, due to the typically hundreds of milligramme protein dosages necessary, highly concentrated formulations are frequently required. The Food and Medication Administration (FDA) of the United States forbids the subcutaneous injection of large doses of drug formulations into patients. It is challenging to create because solutions with hundreds of milligrammes of protein per millilitre are exceedingly viscous, making them challenging to administer. Therefore, creating formulations with reduced viscosities will be quite advantageous. The growth of hydrophobic salts, inorganic salts, or the expansion of lysine or arginine are all methods for doing this. The issue of "syringeability" results from the high viscosity of protein solutions, which affects not only how much power is needed to inject the solution with the proper needles but also how long it takes to finish the injection. Both characteristics significantly affect patient acceptance and compliance.

For the manufacture of biofuels, microalgae feedstock is appropriate and preferred in a variety of ways. For instance, microalgae may be cultivated in any season and can be multiplied without the need for cultivable land or fresh water. They also clean waste water and reduce atmospheric CO₂. Microalgae are not edible, thus they have no impact on the human or animal food chain. The absence of lignocellulosic components in the microalgae cell wall facilitates pretreatment and decreases total production costs. When compared to algae that may consume industrial waste, microalgae use a lot less energy during processing. The use of terrestrial plants, particularly food crops, as feedstocks for the second generation of biofuels is a very contentious subject since it can only happen at the expense of their usage as food and feed. Crop foods also cannot be utilised as substitute liquid fuels since their production is unsustainable due to the high water and arable land requirements. Algal fuel technology is still in its infancy and considerable effort needs to be done to make it commercially acceptable to buyers and investors [3,4].

The methods used to screen for ADAs must be well validated in order to provide reliable, dependable and decisive findings. This action should be done early in the clinical development of a biopharmaceutical and may require continuing monitoring and changes throughout the pre-approval processes. According to previously published guidelines for immunoassays, cut-points, sensitivity, drug tolerance, specificity, accuracy, dilution and repeatability should all be taken into account as validation factors. Due to a lack of consensus over the use of reference standards, the assays are only quasi-quantitative and the experimental techniques for assessing immunogenicity cannot be calibrated. As a result, tests must contain both positive and negative controls, such as purified ADA samples from patients with known immunoglobulin levels and positive controls such blood samples from untreated, healthy persons [5].

Conclusion

Biotechnology will aid in developing new techniques and bettering industrial systems. Processes are in place and a safe replacement requires time and more clinical studies, so this won't happen right immediately. As a result, throughout the next years, we will see a progressive change. Unit operations, which have been in use for a while but will be improved for biopharmaceutical manufacturing demands, may eventually experience a drastic change in production technology for new products. It's probable that recombinant antibodies will be the first items made using these technologies.

Acknowledgement

None.

Conflict of Interest

The authors declare that there is no conflict of interest associated with this manuscript.

References

1. Naylor, Kyla L., Eric McArthur, William D. Leslie and Lisa-Ann Fraser, et al. "The three-year incidence of fracture in chronic kidney disease." Kidney Int 86 (2014): 810-818.

Google Scholar, Crossref, Indexed at

2. Delanaye, Pierre, Bernard E. Dubois, François Jouret and Jean-Marie Krzesinski, et al. "Parathormone and bone-specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis patients: Is it so simple?." Clin Chim Acta 417 (2013): 35-38.

Google Scholar, Crossref, Indexed at

3. Ward, Richard A., Bärbel Schmidt, Jeannine Hullin and Günther F. Hillebrand, et al. "A comparison of on-line hemodiafiltration and high-flux hemodialysis: A prospective clinical study." J Am Soc Nephrol 11 (2000): 2344-2350.

Google Scholar, Crossref, Indexed at

4. Dekker, Marijke, Andreas Pasch, Frank van der Sande and Constantijn Konings, et al."High-flux hemodialysis and high-volume hemodiafiltration improve serum calcification propensity." PLoS One 11 (2016): e0151508.

Google Scholar, Crossref, Indexed at

5. Pelletier, Solenne, Laurence Dubourg, Marie-Christine Carlier and Aoumeur Hadj-Aissa, et al. "The relation between renal function and serum sclerostin in adult patients with CKD." Clin J Am Soc Nephrol 8 (2013): 819-823.

Google Scholar, Crossref, Indexed at